



GEORGIA DEPARTMENT
OF COMMUNITY HEALTH

Georgia Department of Community Health

DRUG UTILIZATION REVIEW BOARD MEETING

Department of Community Health
2 Peachtree Street – **5th Floor Board Room**
Atlanta, Georgia 30303

March 5, 2019

This page intentionally left blank



DRUG UTILIZATION REVIEW BOARD MEETING

AGENDA

2 Peachtree Street - 5th Floor DCH Board Room

Atlanta, Georgia 30303

Tuesday, March 5, 2019

10:00 a.m. to 2:00 p.m.

CALL TO ORDER	<i>Burton L. Lesnick, M.D., FAAP, Chair</i>
MINUTES FROM PREVIOUS MEETING	<i>Chair</i>
EXTERNAL COMMENTS SESSION	<i>Chair</i>
CLINICAL REVIEWS	<i>Afzal Mistry, PharmD, NorthStar Chad Nicholson, PharmD, NorthStar Emily Baker, PharmD, BCPS, NorthStar</i>
➤ New Drugs	
● Fasenra	
● Lokelma	
● Lucemyra	
● Orilissa	
● Solosec	
● Zemdri	
ADJOURNMENT OF OPEN SESSION	<i>Chair</i>
EXECUTIVE SESSION	<i>Nina Bandali, PharmD, Pharmacist Account Manager, Magellan Rx Management</i>
RECONVENING OF OPEN SESSION	<i>Chair</i>
BOARD'S RECOMMENDATIONS AND VOTES	<i>Chair</i>
FUTURE AGENDA ITEMS	<i>Chair</i>
ADJOURNMENT OF MEETING	<i>Chair</i>

This page intentionally left blank

**Department of Community Health
Drug Utilization Review Board (DURB)
MINUTES
Tuesday, November 6, 2018**

MEMBERS PRESENT

Burton L. Lesnick, M.D., FAAP, Chair
Doug Collins, M.D.
Mia Avery, Pharm.D.
Deborah Fincher, M.S., R.Ph.
Robyn Lorys, Pharm.D.
Osgood (Drew) A. Miller, R.Ph.
Matthew Perri, R.Ph., Ph.D.
Brent L. Rollins, R.Ph., Ph.D.
Danny A. Toth, R.Ph.

MEMBERS ABSENT

M. Celeste Fowler, Pharm.D., Vice-Chair
Gurinder J.S. Doad, M.D.
Rod M. Duraski, M.D., FACP, MBA
Glenda Wrenn Gordon, M.D.
J. Russell May, Pharm.D.

Staff

Peter D'Alba, R.Ph., Pharmacy Director, Pharmacy Services
Gilletta Gray, R.Ph., Clinical Manager, Pharmacy Services
Maria Lucas, Pharmacy Program Specialist, Pharmacy Services
Rebecca Morrison, Pharmacy Program Specialist, Pharmacy Services
Rose Marie Duncan, MBA, Operations Analyst-Drug Rebate Program, Pharmacy Services
Lori Garner, MHS, MBA, R.Ph., Pharmacist, SHBP
Karla Forbes, Pharm.D., Program Integrity

NorthStar HealthCare Consulting

Afzal "Fez" Mistry, Pharm.D., Clinical Programs Director
Chad Nicholson, Pharm.D., Clinical Pharmacist

OptumRx

Mark Hall, MBA, PMP, Assoc. Director, Government Markets, Relations & Reform
Talmahjia "Tami" Sweat, Pharm.D., Director, Clinical Management

Magellan Rx Management

Chris Andrews, Pharm.D., VP, Pharmacy Pricing and Value Based Purchasing
Nina Bandali, Pharm.D., Pharmacist Account Manager

Care Management Organizations

Turkesia Robertson-Jones, Pharm.D., CareSource
Cassandra Tancil, Pharm.D., BCPS Amerigroup

Call to Order

The Drug Utilization Review Board (DURB/DUR Board/Board) held its fourth meeting for the calendar year on November 6, 2018. The Chair, Burton L. Lesnick, M.D., FAAP, called the meeting to order at 10:02am.

Minutes from the Previous Meeting

Chair Lesnick asked for corrections or changes to the minutes from the August 7, 2018 meeting. A motion was made (Osgood (Drew) A. Miller, R.Ph.), seconded (Danny A. Toth, R.Ph.), and carried to approve the minutes as written.

Student Introductions

The following students were introduced: Sunpreet Puri (PCOM), Valerie Avant (Mercer), Gretchen Licud (Mercer), and Azizi Ray, Pharm.D., Ph.D, candidate.

External Comments Session

External comments were presented to the Board from the following noted below.

- Amy Wyatt (caregiver of son with Epilepsy) – spoke about antiepileptic drugs, the impact of disruption or changes in medications, and access to medications.
- Kim Jones (Executive Director of NAMI Georgia) – spoke about keeping access to medicines open, injectables being helpful, legislation passed to provide mental health awareness for educators, and solicitation for board members.

Disclosure forms were completed by Amy Wyatt and Kim Jones and were reviewed by the Department.

New Drug Reviews

Clinical information for the following new drugs, in the market six months or more, was presented for discussion and recommendations. The complete detailed drug summary is in the New Drugs for Review section of the DUR Board binder.

Therapeutic Class	Drugs	Presenter
Antimigraine Agents, Other	<i>Aimovig</i>	Afzal “Fez” Mistry, Pharm.D.
Hypophosphatemia Treatments	<i>Crysvita</i>	Chad Nicholson, Pharm.D.
Erythropoiesis Stimulating Proteins	<i>Mircera</i>	Chad Nicholson, Pharm.D.
Ophthalmics, Glaucoma Agents	<i>Rhopressa</i>	Afzal “Fez” Mistry, Pharm.D.
HIV/AIDS	<i>Trogarzo</i>	Chad Nicholson, Pharm.D.
Ophthalmics, Glaucoma Agents	<i>Vyzulta</i>	Afzal “Fez” Mistry, Pharm.D.

**Department of Community Health
Drug Utilization Review Board (DURB)
MINUTES**

Tuesday, November 6, 2018

The Board discussed the drug information, provided comments, and raised questions on the following:

- Crysvisa: Side effect profile – tough drug to take, difficulty in tolerability; Population – 1 in 20,000 but may be much less common, some people may have milder form not yet diagnosed so applicable population may expand for drug ; Diagnosis – very challenging; Physician Administration (difficulty to get to patient); Prior Authorization – clinical trial inclusion criteria, restrictions based on clinical benefit outweighs side effects, limit to specialist; For now, limit to PADL, may be considered for PDL in future if home health feasible; bring back to committee after a period of time to analyze data available.
- Trogarzo: represents different approach for salvage patients; seeing older patients in their 50's and 60's that have been on many drugs and are now resistant; drug used in combination with baseline antiretroviral regimen; after 25 weeks 50% of patients have not responded so need to determine what to do with those patients; consider going back to a specialist to determine if drug is providing benefit or not.
- Aimovig: recommendations for break-through migraines-acute treatment is still taken with this product; OB/GYNs tend to prescribe migraine treatment; specialists usually include neurologists or pain specialists; use of rescue medications decreased; placebo worked well (although statistically significant with Aimovig treatments), important to take a look at numbers vs. percentages.
- Vyzulta: long-term side effects unknown.

DCH Decisions

DCH Decisions from the August 2018 DUR Board meeting were provided in the DCH Decision section of the DUR Board binder.

Upcoming Meetings

The following upcoming meetings were published in the DURB binder:

- Drug Utilization Review Board
2 Peachtree Street NW
5th Floor Board Room
Atlanta, Georgia 30303

Tuesday, February 5, 2019

Thursday, May 2, 2019

Tuesday, August 6, 2019

Tuesday, November 5, 2019

Disclosure Forms

Disclosure forms were received and reviewed by the Department for completeness for all Board members attending the meeting.

Adjournment of Open Session

The DUR Board voted to close the open meeting pursuant to the Open Meeting Act of Georgia Section 50-14-1 – 50-14-6 and pursuant to Federal Law Section 1396R-8B3D. The individuals recorded in attendance with the Board members were from the Department of Community

**Department of Community Health
Drug Utilization Review Board (DURB)
MINUTES**

Tuesday, November 6, 2018

Health, Magellan Rx Management, NorthStar HealthCare Consulting, and OptumRx. CMO representatives, Turkesia Robertson-Jones, Pharm.D. (CareSource), Cassandra Tancil, Pharm.D., BCPS (Amerigroup), and pharmacy students Sunpreet Puri (PCOM), Valerie Avant (Mercer), Gretchen Licud (Mercer), and Azizi Ray, Pharm.D., Ph.D, candidate, also attended the closed session with Board members. A motion was made by Robyn Lorys, Pharm.D., and seconded by Mia Avery, Pharm.D., to adjourn the open session and approve the closed session. There was a unanimous vote approving the closed session. The Chairman, Burton L. Lesnick, M.D., FAAP, adjourned the open session at approximately 11:44am, at which time members took a break then reconvened for the executive (closed) session.

Executive Session

The Executive Session was held from 11:50am to 12:48pm.

Reconvening of Open Session

The DUR Board reconvened for the open session at 12:50pm.

Board's Recommendations to the Department

After all clinical and financial evaluations and discussions, the DUR Board voted and presented the Department with the following recommendations for changes to the Preferred Drug List (PDL) as noted in Attachment A. All motions and votes are noted in Attachment B.

Future Agenda Items

There were no future agenda items noted.

Acknowledgements

The Chairman, Burton L. Lesnick, M.D., FAAP, welcomed Matthew Perri, R.Ph., Ph.D., to the Board and thanked Deborah Fincher, M.S., R.Ph., for her service to the Board.

Conclusion

At the conclusion of the reconvened open session and no other business for discussion, there was a unanimous decision to adjourn the meeting. Chair Lesnick adjourned the meeting at 1:00pm.

THESE MINUTES ARE HEREBY APPROVED AND ADOPTED, THIS THE _____
DAY OF _____, 2018.

Burton L. Lesnick, M.D., FAAP, Chair



The Drug Utilization Review (DUR) Board Reviewed
the Following New Drugs/Classes on
November 6, 2018

Therapeutic Class	Drug Name	DURB Recommendations
Antimigraine Agents, Other		
	<i>Aimovig (Subcutaneous) Injection*</i>	NP/PA
Hypophosphatemia Treatments		
	<i>Crysvita (Subcutaneous) Injection*</i>	NP/PA (for coverage on the PADL)
Erythropoiesis Stimulating Proteins		
	<i>Mircera (Intravenous or Subcutaneous) Injection*</i>	NP/PA
Ophthalmics, Glaucoma Agents		
	<i>Rhopressa (Ophthalmic) Solution*</i>	NP/PA
	<i>Vyzulta (Ophthalmic) Solution*</i>	NP/PA
HIV/AIDS		
	<i>Trogarzo (Intravenous) Injection*</i>	P/PA (for coverage on the PADL)
Anticonvulsants		
	<i>Divalproex Sprinkle (Oral) Capsule</i>	P
	<i>Depakote Sprinkle (Oral) Capsule</i>	NP/PA
	<i>Qudexy XR (Oral) Capsule</i>	NP/PA
Antihyperuricemics		
	<i>Mitigare (Oral) Capsule</i>	P
Antipsychotics		
	<i>Latuda (Oral) Tablet</i>	NP/PA
	<i>Aristada Initio (Intramuscular) Injection</i>	P/PA
Colony Stimulating Factors		
	<i>Fulphila (Subcutaneous) Injection</i>	NP/PA
	<i>Neulasta (Subcutaneous) Injection/Kit</i>	NP/PA
COPD Agents		
	<i>Stiolto Respimat (Inhalation) Spray</i>	P
	<i>Combivent Respimat (Inhalation) Solution</i>	P
	<i>Bevespi (Inhalation) Aerosol</i>	NP/PA
Glucocorticoids, Inhaled		
	<i>Aerospan (Inhalation) Aerosol</i>	NP/PA
Ophthalmics, Anti-Inflammatory/Immunomodulator		
	<i>Restasis (Ophthalmic) Multidose Emulsion</i>	NP/PA



For the following therapeutic classes, the DUR Board recommended no changes:

Alzheimer's Agents	Iron, Oral	Ophthalmics for Allergic Conjunctivitis
Antihistamines, First Generation	Methotrexate	Ophthalmics, Anti-Inflammatories
Antineoplastic Agents	Neuropathic Pain	Otics, Anti-Inflammatory
Topical Antipruritics, Topical	NSAIDs	Otic Antibiotics
Bronchodilators, Beta Agonist	Oncology, Oral - Breast	Progestational Agents
Cough and Cold, Cold	Oncology, Oral - Hematologic	Steroids, Topical High
Cough and Cold, Non-Narcotic	Oncology, Oral - Renal Cell	Steroids, Topical Low
Glucocorticoids, Oral	Oncology, Oral - Skin	Steroids, Topical Very High
Intranasal Rhinitis Agents	Ophthalmic Antibiotic-Steroid Combinations	Thrombopoiesis Stimulating Proteins
Immunomodulators, Atopic Dermatitis	Ophthalmic Antibiotics	

*New drug review; DURB=Drug Utilization Review Board; P=preferred; NP=non-preferred; PA=prior authorization; PADL=Providers' Administered Drug List

Drug Utilization Review Board

Motions - Votes - **New Drugs**

November 6, 2018

New Drug	Drug	PDL Status	Motion - Recommendations	Additional Comments	
Antimigraine Agents, Other	Aimovig (Subcutaneous) Injection	N/A	NP/PA		
Board Members - Present	Motion Maker (v)	Seconded By (v)	VOTES		
(Strike out when absent)			YES (v)	NO (v)	ABSTAIN (v)
1 Avery, Mia, Pharm.D.			√		
2 Collins, Douglas, M.D.			√		
3 Fincher, Deborah W., M.S., R.Ph.			√		
4 Lesnick, Burton, M.D. - Chair			√		
5 Lorys, Robyn Pharm.D.			√		
6 Miller, Osgood (Drew) A., R.Ph.	√		√		
7 Perri, Matthew, R.Ph., Ph.D.			√		
8 Rollins, Brent L., R.Ph., Ph.D.			√		
9 Toth, Danny, R.Ph.		√	√		
TOTAL			9	0	0
Board Members - Absent					
1 Doad, Gurinder J.S., M.D.-					
2 Duraski, Rod, M.D.					
3 Fowler, M. Celeste, Pharm.D. - Vice					
4 Gordon, Glenda Wrenn, M.D.					
5 May, J. Russell (Rusty)					

Drug Utilization Review Board

Motions - Votes - **New Drugs**

November 6, 2018

New Drug	Drug	PDL Status	MOTION - Recommendations	Additional Comments	
Hypophosphatemia Treatments	Crysvita (Subcutaneous) Injection Motion Maker (v)	N/A	NP/PA	For Coverage on the Provider Administered Drug List (PADL)	
Board Members - Present		Secinded By (v)	VOTES		
<i>(Strike out, when absent)</i>			YES (v)	NO (v)	ABSTAIN (v)
1 Avery, Mia, Pharm.D.		√	√		
2 Collins, Douglas, M.D.			√		
3 Fincher, Deborah W., M.S., R.Ph.			√		
4 Lesnick, Burton, M.D. - Chair			√		
5 Lorys, Robyn Pharm.D.		√	√		
6 Miller,Osgood (Drew) A., R.Ph.			√		
7 Perri, Matthew, R.Ph., Ph.D.			√		
8 Rollins, Brent L., R.Ph., Ph.D.		√			
9 Toth, Danny, R.Ph.		√			
TOTAL			9	0	0
Board Members - Absent					
1 Doad, Gurinder J.S., M.D.-					
2 Duraski, Rod, M.D.					
3 Fowler, M. Celeste, Pharm.D. - Vice					
4 Gordon, Glenda Wrenn, M.D.					
5 May, J. Russell (Rusty)					

Drug Utilization Review Board

Motions - Votes - **New Drugs**

November 6, 2018

New Drug	Drug	PDL Status	MOTION - Recommendations	Additional Comments		
Erythropoiesis Stimulating Proteins Board Members - Present (Strike out, when absent)	Mircera (Intravenous or Subcutaneous) Injection	N/A	NP/PA	For Coverage on the Provider Administered Drug List (PADL)		
				VOTES		
	Motion Maker (v)	Seconded By (v)	YES (v)	NO (v)	ABSTAIN (v)	
	1 Avery, Mia, Pharm.D.	√		√		
	2 Collins, Douglas, M.D.			√		
	3 Fincher, Deborah W., M.S., R.Ph.			√		
	4 Lesnick, Burton, M.D. - Chair			√		
	5 Lorys, Robyn Pharm.D.		√	√		
	6 Miller, Osgood (Drew) A., R.Ph.			√		
	7 Perri, Matthew, R.Ph., Ph.D.			√		
8 Rollins, Brent L., R.Ph., Ph.D.			√			
9 Toth, Danny, R.Ph.			√			
TOTAL			9	0	0	
Board Members - Absent						
1 Doad, Gurinder J.S., M.D.-						
2 Duraski, Rod, M.D.						
3 Fowler, M. Celeste, Pharm.D. - Vice						
4 Gordon, Glenda Wrenn, M.D.						
5 May, J. Russell (Rusty)						

Drug Utilization Review Board

Motions - Votes - **New Drugs**

November 6, 2018

New Drug	Drug	PDL Status	Motion - Recommendations	Additional Comments	
Ophthalmics, Glaucoma Agents	Rhopressa (Ophthalmic) Solution	N/A	NP/PA		
	Vyzulta (Ophthalmic) Solution*	N/A	NP/PA		
Board Members - Present	Motion Maker (v)	Seconded By (v)	VOTES		
(Strike out, when absent)			YES (v)	NO (v)	ABSTAIN (v)
1 Avery, Mia, Pharm.D.			√		
2 Collins, Douglas, M.D.			√		
3 Fincher, Deborah W., M.S., R.Ph.			√		
4 Lesnick, Burton, M.D. - Chair			√		
5 Lorys, Robyn Pharm.D.			√		
6 Miller, Osgood (Drew) A., R.Ph.			√		
7 Perri, Matthew, R.Ph., Ph.D.		√	√		
8 Rollins, Brent L., R.Ph., Ph.D.	√		√		
9 Toth, Danny, R.Ph.			√		
TOTAL			9	0	0
Board Members - Absent					
1 Doad, Gurinder J.S., M.D.-					
2 Duraski, Rod, M.D.					
3 Fowler, M. Celeste, Pharm.D. - Vice					
4 Gordon, Glenda Wrenn, M.D.					
5 May, J. Russell (Rusty)					

Drug Utilization Review Board

Motions - Votes - **New Drugs**

November 6, 2018

New Drug	Drug	PDL Status	MOTION - Recommendations	Additional Comments	
HIV/AIDS	Trogarzo (Intravenous) Injection	N/A	P/PA	For Coverage on the Provider Administered Drug List (PADL)	
Board Members - Present	Motion Maker (v)	Seconded By (v)	VOTES		
<i>(Strike out, when absent)</i>			YES (v)	NO (v)	ABSTAIN (v)
1 Avery, Mia, Pharm.D.			√		
2 Collins, Douglas, M.D.			√		
3 Fincher, Deborah W., M.S., R.Ph.	√		√		
4 Lesnick, Burton, M.D. - Chair			√		
5 Lorys, Robyn Pharm.D.			√		
6 Miller,Osgood (Drew) A., R.Ph.			√		
7 Perri, Matthew, R.Ph., Ph.D.			√		
8 Rollins, Brent L., R.Ph., Ph.D.		√	√		
9 Toth, Danny, R.Ph.			√		
TOTAL			9	0	0
Board Members - Absent					
1 Doad, Gurinder J.S., M.D.-					
2 Duraski, Rod, M.D.					
3 Fowler, M. Celeste, Pharm.D. - Vice					
4 Gordon, Glenda Wrenn, M.D.					
5 May, J. Russell (Rusty)					

Drug Utilization Review Board
 Motions - Votes - Supplemental Rebate Drugs
 November 6, 2018

Supplemental Rebates Class Review		Drug	PDL Status	Motion - Recommendations	Additional Comments	
Anticonvulsants		Divalproex Sprinkle (Oral) Capsule	NP/PA	P		
		Depakote Sprinkle (Oral) Capsule	P	NP/PA		
		Qudexy XR (Oral) Capsule	P/PA	NP/PA		
Board Members - Present		Motion Maker (v)	Seconded By (v)	VOTES		
<i>(Strike out, when absent)</i>				YES (v)	NO (v)	ABSTAIN (v)
1	Avery, Mia, Pharm.D.			√		
2	Collins, Douglas, M.D.			√		
3	Fincher, Deborah W., M.S., R.Ph.		√	√		
4	Lesnick, Burton, M.D. - Chair			√		
5	Lorys, Robyn Pharm.D.			√		
6	Miller,Osgood (Drew) A., R.Ph.	√		√		
7	Perri, Matthew, R.Ph., Ph.D.			√		
8	Rollins, Brent L., R.Ph., Ph.D.			√		
9	Toth, Danny, R.Ph.			√		
			TOTAL	9	0	0
Board Members - Absent						
1	Doad, Gurinder J.S., M.D.-					
2	Duraski, Rod, M.D.					
3	Fowler, M. Celeste, Pharm.D. - Vice					
4	Gordon, Glenda Wrenn, M.D.					
5	May, J. Russell (Rusty)					

Drug Utilization Review Board
 Motions - Votes - Supplemental Rebate Drugs
 November 6, 2018

Supplemental Rebates Class Review		Drug	PDL Status	Motion - Recommendations	Additional Comments		
Antihyperuricemics		Mitigare (Oral) Capsule Motion Maker (v)	NP/PA Seconded By (v)	P			
Board Members - Present <i>(Strike out when absent)</i>				VOTES			
				YES (v)	NO (v)	ABSTAIN (v)	
1	Avery, Mia, Pharm.D.			√			
2	Collins, Douglas, M.D.			√			
3	Fincher, Deborah W., M.S., R.Ph.	√		√			
4	Lesnick, Burton, M.D. - Chair			√			
5	Lorys, Robyn Pharm.D.			√			
6	Miller,Osgood (Drew) A., R.Ph.			√			
7	Perri, Matthew, R.Ph., Ph.D.			√			
8	Rollins, Brent L., R.Ph., Ph.D.		√	√			
9	Toth, Danny, R.Ph.			√			
			TOTAL	9	0	0	
Board Members - Absent							
1	Doad, Gurinder J.S., M.D.-						
2	Duraski, Rod, M.D.						
3	Fowler, M. Celeste, Pharm.D. - Vice						
4	Gordon, Glenda Wrenn, M.D.						
5	May, J. Russell (Rusty)						

Drug Utilization Review Board
 Motions - Votes - Supplemental Rebate Drugs
 November 6, 2018

Supplemental Rebates Class Review		Drug	PDL Status	Motion - Recommendations	Additional Comments	
Antipsychotics		Latuda (Oral) Tablet	P/PA	NP/PA		
		Aristada Initio (Intramuscular) Injection	N/A	P/PA		
Board Members - Present <i>(Strike out, when absent)</i>		Motion Maker (v)	Seconded By (v)	VOTES		
				YES (v)	NO (v)	ABSTAIN (v)
1	Avery, Mia, Pharm.D.			√		
2	Collins, Douglas, M.D.			√		
3	Fincher, Deborah W., M.S., R.Ph.			√		
4	Lesnick, Burton, M.D. - Chair			√		
5	Lorys, Robyn Pharm.D.	√		√		
6	Miller, Osgood (Drew) A., R.Ph.			√		
7	Perri, Matthew, R.Ph., Ph.D.			√		
8	Rollins, Brent L., R.Ph., Ph.D.			√		
9	Toth, Danny, R.Ph.		√	√		
			TOTAL	9	0	0
Board Members - Absent						
1	Doad, Gurinder J.S., M.D.-					
2	Duraski, Rod, M.D.					
3	Fowler, M. Celeste, Pharm.D. - Vice					
4	Gordon, Glenda Wrenn, M.D.					
5	May, J. Russell (Rusty)					

Drug Utilization Review Board
 Motions - Votes - Supplemental Rebate Drugs
 November 6, 2018

Supplemental Rebates Class Review		Drug	PDL Status	Motion - Recommendations	Additional Comments	
Colony Stimulating Factors		Fulphila (Subcutaneous) Injection	N/A	NP/PA		
		Neulasta(Subcutaneous) Injection/Kit	P/PA	NP/PA		
Board Members - Present <small>(Strike out, when absent)</small>		Motion Maker (v)	Seconded By (v)	VOTES		
				YES (v)	NO (v)	ABSTAIN (v)
1	Avery, Mia, Pharm.D.			√		
2	Collins, Douglas, M.D.	√		√		
3	Fincher, Deborah W., M.S., R.Ph.			√		
4	Lesnick, Burton, M.D. - Chair			√		
5	Lorys, Robyn Pharm.D.			√		
6	Miller,Osgood (Drew) A., R.Ph.		√	√		
7	Perri, Matthew, R.Ph., Ph.D.			√		
8	Rollins, Brent L., R.Ph., Ph.D.			√		
9	Toth, Danny, R.Ph.			√		
			TOTAL	9	0	0
Board Members - Absent						
1	Doad, Gurinder J.S., M.D.-					
2	Duraski, Rod, M.D.					
3	Fowler, M. Celeste, Pharm.D. - Vice					
4	Gordon, Glenda Wrenn, M.D.					
5	May, J. Russell (Rusty)					

Drug Utilization Review Board
 Motions - Votes - Supplemental Rebate Drugs
 November 6, 2018

Supplemental Rebates Class Review		Drug	PDL Status	Motion - Recommendations	Additional Comments	
COPD Agents		Stiolto Respimat (Inhalation) Spray	NP/PA	P		
		Combivent Respimat (Inhalation) Solution	NP/PA	P		
		Bevespi (Inhalation) Aerosol	P	NP/PA		
Board Members - Present		Motion Maker (v)	Seconded By (v)	VOTES		
(Strike out, when absent)				YES (v)	NO (v)	ABSTAIN (v)
1	Avery, Mia, Pharm.D.			√		
2	Collins, Douglas, M.D.			√		
3	Fincher, Deborah W., M.S., R.Ph.			√		
4	Lesnick, Burton, M.D. - Chair			√		
5	Lorys, Robyn Pharm.D.			√		
6	Miller,Osgood (Drew) A., R.Ph.			√		
7	Perri, Matthew, R.Ph., Ph.D.		√	√		
8	Rollins, Brent L., R.Ph., Ph.D.	√		√		
9	Toth, Danny, R.Ph.			√		
			TOTAL	9	0	0
Board Members - Absent						
1	Doad, Gurinder J.S., M.D.-					
2	Duraski, Rod, M.D.					
3	Fowler, M. Celeste, Pharm.D. - Vice					
4	Gordon, Glenda Wrenn, M.D.					
5	May, J. Russell (Rusty)					

Drug Utilization Review Board
 Motions - Votes - Supplemental Rebate Drugs
 November 6, 2018

Supplemental Rebates Class Review		Drug	PDL Status	Motion - Recommendations	Additional Comments	
Glucocorticoids, Inhaled		Aerospan (Inhalation) Aerosol	P	NP/PA		
Board Members - Present		Motion Maker (v)	Seconded By (v)	VOTES		
<i>(Strike out when absent)</i>				YES (v)	NO (v)	ABSTAIN (v)
1	Avery, Mia, Pharm.D.			√		
2	Collins, Douglas, M.D.			√		
3	Fincher, Deborah W., M.S., R.Ph.		√	√		
4	Lesnick, Burton, M.D. - Chair			√		
5	Lorys, Robyn Pharm.D.			√		
6	Miller, Osgood (Drew) A., R.Ph.	√		√		
7	Perri, Matthew, R.Ph., Ph.D.			√		
8	Rollins, Brent L., R.Ph., Ph.D.			√		
9	Toth, Danny, R.Ph.			√		
TOTAL				9	0	0
Board Members - Absent						
1	Doad, Gurinder J.S., M.D.-					
2	Duraski, Rod, M.D.					
3	Fowler, M. Celeste, Pharm.D. - Vice					
4	Gordon, Glenda Wrenn, M.D.					
5	May, J. Russell (Rusty)					

Drug Utilization Review Board
 Motions - Votes - Supplemental Rebate Drugs
 November 6, 2018

Supplemental Rebates Class Review		Drug	PDL Status	Motion - Recommendations	Additional Comments	
Ophthalmics, Anti-Inflammatory/Immunomodulator		Restasis (Ophthalmic) Multidose Emulsion Motion Maker (v)	P Seconded By (v)	NP/PA YES (v)	VOTES	
Board Members - Present <i>(Strike out when absent)</i>					NO (v)	ABSTAIN (v)
1	Avery, Mia, Pharm.D.		√	√		
2	Collins, Douglas, M.D.	√		√		
3	Fincher, Deborah W., M.S., R.Ph.			√		
4	Lesnick, Burton, M.D. - Chair			√		
5	Lorys, Robyn Pharm.D.			√		
6	Miller, Osgood (Drew) A., R.Ph.			√		
7	Perri, Matthew, R.Ph., Ph.D.			√		
8	Rollins, Brent L., R.Ph., Ph.D.			√		
9	Toth, Danny, R.Ph.			√		
			TOTAL	9	0	0
Board Members - Absent						
1	Doad, Gurinder J.S., M.D.-					
2	Duraski, Rod, M.D.					
3	Fowler, M. Celeste, Pharm.D. - Vice					
4	Gordon, Glenda Wrenn, M.D.					
5	May, J. Russell (Rusty)					

Important Update DCH Decision Document

Listed below are Preferred Drug List changes for the State of Georgia Fee-For-Service Medicaid and PeachCare for Kids Programs

Effective January 1, 2019 (see chart below)

DCH rebate vendor Magellan Medicaid Administration (MMA) has reviewed SFY2019 supplemental rebate offers with DCH and also reviewed specific drug categories at the November 2018 DURB meeting. The PDL/PADL decisions or PDL/PADL changes for new drugs or categories reviewed during the November DURB meeting are outlined below. **Those drugs highlighted in red indicate a change from current PDL status.** For a full listing of our PDL, go to www.dch.georgia.gov/pharmacy and select the “preferred product list” option.

PREFERRED AGENTS	NON-PREFERRED AGENTS
ONLY DRUGS reviewed during the November 2018 DURB meeting as either new to market or a change in PDL status are listed	
ANTICONVULSANTS	
DIVALPROEX SPRINKLE	DEPAKOTE SPRINKLE
	QUDEXY XR
ANTIHYPURICEMICS	
MITIGARE (effective 12/1/18)	
ANTIMIGRAINE AGENTS, OTHER	
	AIMOVIG
ANTIPSYCHOTICS	
ARISTADA INITIO	LATUDA
COLONY STIMULATING FACTORS	
	FULPHILA
	NEULASTA
COPD AGENTS	
COMBIVENT RESPIMAT	BEVESPI
STIOLTO RESPIMAT	
ERYTHROPOIESIS STIMULATING PROTEINS	
	MIRCERA

PREFERRED AGENTS	NON-PREFERRED AGENTS
GLUCOCORTICOIDS, INHALED	
	AEROSPAN
HIV / AIDS	
TROGARZO (PADL only)	
HYPOPHOSPHATEMIA TREATMENTS	
	CRYSVITA (PADL only)
OPHTHALMICS, ANTI-INFLAMMATORY/IMMUNOMODULATOR	
	RESTASIS MULTIDOSE
OPHTHALMICS, GLAUCOMA AGENTS	
	RHOPRESSA
	VYZULTA

**Georgia Department of Community Health (GDCH)
Opportunities for Pharmaceutical Manufacturer Input on Clinical
Recommendations and Clinical Management Strategies by the
Drug Utilization Review Board**

Clinical Information and Clinical Management Strategies relevant to the GDCH Medicaid Fee-For-Service program will be presented to the Drug Utilization Review Board (DURB) at each meeting through OptumRx by its vendor NorthStar HealthCare Consulting (NHC). Manufacturer input on new and existing drugs is welcomed and appreciated using these opportunities. **Please note that new drug entities are generally not reviewed by the DURB until the drug has been on the market for at least 6 months.**

Ongoing Opportunity:

DUR Board Meeting Process: Drugs, therapeutic classes and/or supplemental rebate classes under review will be posted to the DCH website at <http://dch.georgia.gov/durb-meeting-information> approximately 30 days prior to the Manufacturers' Forum. Input specific to the drugs under review from manufacturers are made directly to NHC via GAMedicaid@nhc-llc.com and reported as appropriate by NHC at subsequent DURB meetings. NHC will pass relevant manufacturer-submitted electronic materials to the DURB members via a secure FTP site.

Upon review of information, and based on its expertise and discussions, the DURB makes recommendations to GDCH.

Opportunity to Appeal to GDCH:

GDCH Review Process: DURB recommendations are reviewed by GDCH for final decisions. Manufacturers may request an appeal meeting directly with GDCH after conclusion of each quarterly DURB meeting and **this appeal meeting must be conducted within 10 business days following the DURB meeting.** **Contact: Shirmary Hodges at (404) 656-4044 or shodges@dch.ga.gov**

Presentation Opportunity:

Manufacturers' Forum: A forum prior to each relevant DURB meeting whereby manufacturers may present:

- 1) Clinical information relevant to a new drug on the market or a drug that is part of a therapeutic or supplemental rebate class under review by the DURB at the next meeting.
- 2) Clinical information relevant to ongoing NHC/OptumRx clinical management strategies (e.g. review of drug benefit plan designs, new drugs coming to market, new indications, etc.) as deemed necessary by NHC/OptumRx.

Please see the Manufacturers' Forum Announcement at <http://dch.georgia.gov/durb-meeting-information>.

**Questions not addressed in this document may be sent to NorthStar
HealthCare Consulting by e-mail: GAMedicaid@nhc-llc.com**

This page intentionally left blank

2019

Upcoming Meetings

Drug Utilization Review Board Meeting

2 Peachtree Street, N.W.

5th Floor Board Room

Atlanta, Georgia 30303

Tuesday, March 5, 2019: 10:00am – 2:00pm

Tuesday, May 7, 2019: TBD

Tuesday, August 6, 2019: TBD

Tuesday, November 5, 2019: TBD

This page intentionally left blank

Drug Utilization Review Board

Board Member	Credentials	Specialty/Area of Expertise	Company Name
Burton L. Lesnick, Chair	M.D., FAAP	Pediatrics/Pediatric Pulmonology	Children's Healthcare of Atlanta
M. Celeste Fowler, Vice-Chair	Pharm.D., HCMBA	340B Pharmacy	Piedmont Henry Hospital
Mia Avery	Pharm.D.	Oncology Pharmacy	Emory University Hospital Winship Cancer Institute
Douglas C. Collins	M.D.	Hematology/Oncology	Metro Hematology-Oncology, PC
Alton Condra III	R.Ph.	HIV/AIDS Pharmacy - Infectious Disease Program	Grady Memorial Hospital
Gurinder J.S. Doad	M.D., Ph.D.	Family Practice	Southwest Georgia Family Medicine and Mercer University School of Medicine
Rod M. Duraski	M.D., FACP, MBA	Internal Medicine	West Georgia Health
Glenda Gordon	M.D.	Psychiatry, Academia - Professor	Morehouse School of Medicine
Robyn Lorys	Pharm.D.	Academia - Professor	Mercer University College of Pharmacy
J. Russell May	Pharm.D.	Academia - Professor	University of Georgia College of Pharmacy
Drew A. Miller	R.Ph.	Retail Pharmacy	Wynn's Pharmacy
Matthew Perri III	Ph.D., R.Ph.	Academia - Professor	University of Georgia College of Pharmacy
Brent L. Rollins	R.Ph., Ph.D.	Academia - Professor	Philadelphia College of Osteopathic Medicine School of Pharmacy
Danny A. Toth	R.Ph.	Pharmacy Benefit Plans	Timber Ridge Consultants, LLC